US EditionPublished • loading... • Updated
BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Overweight Rating from Analysts at Barclays
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Overweight Rating from Analysts at Barclays
Barclays started coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) in a report issued on Wednesday morning. The firm issued an overweight rating and a $80.00 price objective on the biotechnology company’s stock. A number of other research firms have also weighed in on BMRN. Morgan Stanley cut their target price on shares […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
